Spruce Biosciences Receives FDA Orphan Drug Designation for SPR001 for the Treatment of Congenital Adrenal Hyperplasia

Clinical-stage biotech granted orphan drug designation for the treatment of CAH, a rare endocrine disease SAN FRANCISCO, Dec. 4, 2017 -- (Healthcare Sales & Marketing Network) -- Spruce Biosciences, a clinical-stage biotechnology company developing nov... Biopharmaceuticals, FDA Spruce Biosciences, congenital adrenal hyperplasia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news